Ibrutinib in chronic lymphocytic leukaemia: alone or in combination?

Affiliations

Comment

Tadeusz Robak. Lancet Oncol. 2016 Feb.

. 2016 Feb;17(2):129-131.

doi: 10.1016/S1470-2045(15)00519-7. Epub 2015 Dec 5.

¹ Department of Hematology, Medical University of Lodz, 93-510 Lodz, Ul Ciolkowskiego 2, Poland. Electronic address: robaktad@csk.umed.lodz.pl.

No abstract available

Comment on

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M; HELIOS investigators. Chanan-Khan A, et al. Lancet Oncol. 2016 Feb;17(2):200-211. doi: 10.1016/S1470-2045(15)00465-9. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26655421 Clinical Trial.